Nesina (nes-SEE-na, alogliptin) will compete for your prescription in a crowded market of gliptins for type 2 diabetes

August 2013

Nesina (nes-SEE-na, alogliptin) will compete for your prescription in a crowded market of gliptins for type 2 diabetes.

This new DPP-4 inhibitor is a "me too"...similar to Januvia (sitagliptin), Onglyza (saxagliptin), and Tradjenta (linagliptin).

Continue to recommend lifestyle changes and metformin first.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: MD includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote